NCT00535405View on ClinicalTrials.gov

A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,289

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Hypercholesterolemia
Interventions
DRUG

Atorvastatin 10 mg

Atorvastatin 10 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks

DRUG

Ezetimibe 10 mg/simvastatin 20 mg

Ezetimibe 10 mg/simvastatin 20 mg and Placebo for atorvastatin once daily for 12 weeks

DRUG

Atorvastatin 20 mg

Atorvastatin 20 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks

DRUG

Ezetimibe 10 mg/simvastatin 40 mg

Ezetimibe 10 mg/simvastatin 40 mg and Placebo for atorvastatin once daily for 12 weeks

DRUG

Atorvastatin 40 mg

Atorvastatin 40 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks

All Listed Sponsors
collaborator

Merck Shering-Plough JV Study

UNKNOWN

lead

Organon and Co

INDUSTRY

NCT00535405 - A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128) | Biotech Hunter | Biotech Hunter